Атипичная тератоид-рабдоидная опухоль: обзор современных методов диагностики и терапии
https://doi.org/10.24287/1726-1708-2018-17-3-120-126
Аннотация
Об авторах
Ж. С. Супик
ФГБУ «Национальный медицинский исследовательский центр детской гематологии, онкологии и иммунологии им. Дмитрия Рогачева»
Россия
Россия
Супик Жанна Сергеевна, врач-детский онколог боксированного, отделение гематологии/онкологии
117997, Москва, ГСП-7, ул. Саморы Машела, 1
Л. И. Папуша
ФГБУ «Национальный медицинский исследовательский центр детской гематологии, онкологии и иммунологии им. Дмитрия Рогачева»
Россия
Россия
А. Е. Друй
ФГБУ «Национальный медицинский исследовательский центр детской гематологии, онкологии и иммунологии им. Дмитрия Рогачева»
Россия
Россия
Л. А. Ясько
ФГБУ «Национальный медицинский исследовательский центр детской гематологии, онкологии и иммунологии им. Дмитрия Рогачева»
Россия
Россия
А. И. Карачунский
ФГБУ «Национальный медицинский исследовательский центр детской гематологии, онкологии и иммунологии им. Дмитрия Рогачева»
Россия
Россия
Список литературы
1. Ostrom Q.T., de Blank P.M., Kruchko C., Petersen C.M., Liao P., Finlay J.L., et al. Alex's Lemonade Stand Foundation infant and childhood primary brain and central nervous system tumors diagnosed in the United States in 2007–2011. Neuro Oncol 2015; 16 (Suppl 10): x1–x36.
2. Tekautz T.M., Fuller C.E., Blaney S., Fouladi M., Broniscer A., Merchant T.E., et al. Atypical teratoid/rhabdoid tumors (ATRT): improved survival in children 3 years of age and older with radiation therapy and high-dose alkylator-based chemotherapy. J Clin Oncol 2005; 23 (7): 1491–9.
3. Hilden J.M., Meerbaum S., Burger P., Finlay J., Janss A., Scheithauer B.W., et al. Central nervous system atypical teratoid/rhabdoid tumor: results of therapy in children enrolled in a registry. J Clin Oncol 2004; 22 (14): 2877–84.
4. Seeringer A., Bartelheim K., Kerl K., Hasselblatt M., Leuschner I., Rutkowski S., et al. Feasibility of intensive multimodal therapy in infants affected by rhabdoid tumors – experience of the EU-RHAB registry. Klin Padiatr 2014; 226 (3): 143–8.
5. Bourdeaut F., Freneaux P., Thuille B., Bergeron C., Laurence V., Brugières L., et al. Extra-renal non-cerebral rhabdoid tumours. Pediatr Blood Cancer 2008; 51 (3): 363–8.
6. Rizzo D., Freneaux P., Brisse H., Louvrier C., Lequin D., Nicolas A., et al. SMARCB1 deficiency in tumors from the peripheral nervous system: a link between schwannomas and rhabdoid tumors? Am J Surg Pathol 2012; 36 (7): 964–72.
7. Seeringer A., Reinhard H., Hasselblatt M., Schneppenheim R., Siebert R., Bartelheim K., et al. Synchronous congenital malignant rhabdoid tumor of the orbit and atypical teratoid/rhabdoid tumor – feasibility and efficacy of multimodal therapy in a long-term survivor. Cancer Genet 2014; 207 (9): 429–33.
8. Beckwith J.B., Palmer N.F. Histopa-thology and prognosis of Wilms tumors: results from the First National Wilms’ Tumor Study. Cancer 1978; 41 (5): 1937–48.
9. Rorke L.B., Packer R.J., Biegel J.A. Central nervous system atypical teratoid/rhabdoid tumors of infancy and childhood: definition of an entity. J Neurosurg 1996; 85 (1): 56–65.
10. Louis D.N., Ohgaki H., Wiestler O.D., Cavenee W.K., Burger P.C., Jouvet A., et al. The 2007 WHO Classification of Tumours of the Central Nervous System. Acta Neuropathol 2007, Aug; 114 (2): 97–109.
11. Judkins A.R., Eberhart C.G., Wesseling P. Atypical teratoid/ rhabdoid tumor. In: World Health Organization classification of tumours: pathology and genetics of central nervous system. Lyon: IARC Press 2007; 147–9.
12. Lee R.S., Stewart C., Carter S.L., Ambrogio L., Cibulskis K., Sougnez C., et al. A remarkably simple genome underlies highly malignant pediatric rhabdoid cancers. J Clin Invest 2012; 122 (8): 2983–8.
13. Biegel J.A., Zhou J.Y., Rorke L.B., Stenstrom C., Wainwright L.M., Fogelgren B. Germ-line and acquired mutations of INI1 in atypical teratoid and rhabdoid tumors. Cancer Res 1999; 59: 74–9.
14. Versteege I., Sevenet N., Lange J., Rousseau-Merck M.F., Ambros P., Handgretinger R., et al. Truncating mutations of hSNF5/INI1 in aggressive pediatric cancer. Nature 1998; 394; 203–6.
15. Hasselblatt M., Nagel I., Oyen F., Bartelheim K., Russell RB., Schüller U., et al. SMARCA4-mutated atypical teratoid/rhabdoid tumors are ssociated with inherited germline alterations and poor prognosis. Acta Neuropathol 2014; 128: 453–6.
16. Simone T.S., Tomita T. Rhabdoid Tumor Predisposition Syndrome. Pediatric and Developmental Pathology. 2015; 18, 49–58.
17. Johann P.D., Erkek S., Zapatka M., Kerl K. Atypical Teratoid/Rhabdoid Tumors Are Comprised of Three Epigenetic Subgroups with Distinct Enhancer Landscapes. Cancer Cell 2016 Mar 14; 29 (3): 379–93.
18. Hasselblatt M., Oyen F., Gesk S., Kordes U., Wrede B., Bergmann M., et al. Cribriform neuroepithelial tumor (CRINET): a nonrhabdoid ventricular tumor with INI1 loss and relatively favorable prognosis. J Neuropathol Exp Neurol 2009; 68 (12): 1249–55.
19. Schneppenheim R., Fruhwald M.C., Gesk S., Hasselblatt M., Jeibmann A., Kordes U., et al. Germline nonsense mutation and somatic inactivation of SMARCA4/BRG1 in a family with rhabdoid tumor predisposition syndrome. Am J Hum Genet 2010; 86 (2): 279–84.
20. Hasselblatt M., Thomas C., Hovestadt V., Johann P., Frühwald M., Kool M., et al. Cribriform neuroepithelial tumor (CRINET): molecular characterization of a SMARCB1-deficient non-rhabdoid tumor with favorable long-term outcome. Neuro Oncol 2016 Jun; 18 (Suppl 3).
21. Torchia J., Picard D., Lafay-Cousin L., Hawkins C.E., Kim S.K., Letourneau L., et al. Molecular subgroups of atypical teratoid rhabdoid tumours in children: an integrated genomic and clinicopathological analysis. Lancet Oncol 2015; 165: 569–82.
22. Torchia J., Golbourn B., Feng S., Ho K.C., Sin-Chan P., Vasiljevic A., et al. Integrated (epi)-Genomic Analyses Identify Subgroup-Specific Therapeutic Targets in CNS Rhabdoid Tumors. Cancer Cell 2016 Dec 12; 30 (6): 891–908.
23. Athale U.H., Duckworth J., Odame I., Barr R. Childhood atypical teratoid rhabdoid tumor of the central nervous system: a meta-analysis of observational studies. J Pediatr Hematol Oncol 2009; 31 (9): 651–63.
24. Chi S.N., Zimmerman M.A., Yao X., Cohen K.J., Burger P., Biegel J.A., et al. Intensive multimodality treatment for children with newly diagnosed CNS atypical teratoid rhabdoid tumor. J Clin Oncol 2009; 27 (3): 385–9.
25. Lafay-Cousin L., Hawkins C., Carret A.S., Johnston D., Zelcer S., Wilson B., et al. Central nervous system atypical teratoid rhabdoid tumours: the Canadian Paediatric Brain Tumour Consortium experience. Eur J Cancer 2012; 48 (3): 353–9.
26. Finkelstein-Shechter T., Gassas A., Mabbott D., Huang A., Bartels U., Tabori U., et al. Atypical teratoid or rhabdoid tumors: improved outcome with high-dose chemotherapy. J Pediatr Hematol Oncol 2010; 32 (5): e182–e186.
27. Geyer J.R., Sposto R., Jennings M., Boyett J.M., Axtell RA., Breiger D., et al. Multiagent chemotherapy and deferred radiotherapy in infants with malignant brain tumors: a report from the Children's Cancer Group. J Clin Oncol 2005; 23 (30): 7621–31.
28. Buscariollo D.L., Park H.S., Roberts K.B., Yu J.B. Survival outcomes in atypical teratoid rhabdoid tumor for patients undergoing radiotherapy in a Surveillance, Epidemiology, and End Results analysis. Cancer 2012; 118 (17): 4212–9.
29. Kralik S.F., Ho C.Y., Finke W., Buchs-baum J.C., Haskins C.P., Shih C.S. Radiation necrosis in pediatric patients with brain tumors treated with proton radiotherapy. AJNR Am J Neuroradiol 2015; 36 (8): 1572–8.
30. De Amorim Bernstein K., Sethi R., Trofimov A., Zeng C., Fullerton B., Yeap B.Y., et al. Early clinical outcomes using proton radiation for children with central nervous system atypical teratoid rhabdoid tumors. Int J Radiat Oncol Biol Phys 2013; 86 (1): 114–20.
31. McGovern S.L., Okcu M.F., Munsell M.F., Kumbalasseriyil N., Grosshans D.R., McAleer M.F., et al. Outcomes and acute toxicities of proton therapy for pediatric atypical teratoid/rhabdoid tumor of the central nervous system. Int J Radiat Oncol Biol Phys 2014; 90 (5): 1143–52.
32. Weber D.C., Ares C., Malyapa R., Albertini F., Calaminus G., Kliebsch U., et al. Tumor control and QoL outcomes of very young children with atypical teratoid/rhabdoid tumor treated with focal only chemo-radiation therapy using pencil beam scanning proton therapy. J Neurooncol 2015; 121 (2): 389–97.
33. Olson T.A., Bayar E., Kosnik E., Hamo-udi A.B., Klopfenstein K.J., Pieters R.S., et al. Successful treatment of disseminated central nervous system malignant rhabdoid tumor. J Pediatr Hematol Oncol 1995; 17 (1): 71–5.
34. Park E.S., Sung K.W., Baek H.J., Park K.D., Park H.J., Won S.C., et al. Tandem high-dose chemotherapy and autologous stem cell transplantation in young children with atypical teratoid/rhabdoid tumor of the central nervous system. Korean Med Sci 2012; 27 (2): 135–40.
35. Slavc I., Chocholous M., Leiss U., Haberler C., Peyrl A., Azizi A.A., et al. Atypical teratoid rhabdoid tumor: improved long-term survival with an intensive multimodal therapy and delayed radiotherapy. The Medical University of Vienna Experience 1992–2012. Cancer Med 2014; 3 (1): 91–100.
36. Wetmore C., Boyett J., Li S., Lin T., Bendel A., Gajjar A., et al. Alisertib is active as single agent in recurrent atypical teratoid rhabdoid tumors in 4 children. Neuro Oncol 2015; 176: 882–8.
Рецензия
Для цитирования:
Супик Ж.С., Папуша Л.И., Друй А.Е., Ясько Л.А., Карачунский А.И. Атипичная тератоид-рабдоидная опухоль: обзор современных методов диагностики и терапии. Вопросы гематологии/онкологии и иммунопатологии в педиатрии. 2018;17(3):120-126. https://doi.org/10.24287/1726-1708-2018-17-3-120-126
For citation:
Supik Z.S., Papusha L.I., Drui A.Y., Yasko L.A., Karachunskiy A.I. Atypical teratoid rhabdoid tumor: review of literature. Pediatric Hematology/Oncology and Immunopathology. 2018;17(3):120-126. (In Russ.) https://doi.org/10.24287/1726-1708-2018-17-3-120-126
Просмотров: 2182
Послать статью по эл. почте 
